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The clinical relevance of angiopoietin-2
(Ang2) in chronic lymphocytic leukemia
(CLL) was previously suggested by the
association between high Ang2, and
shorter progression-free survival reported
in small series of patients. Here, we evalu-
ated Ang2 glycoprotein levels in plasma
samples collected from a multicentric co-
hort of CLL patients (n  316) using an
enzyme-linked immunosorbent assay
method, and we investigated its prognos-
tic role in relation to time to first treatment
(TTFT) and overall survival. Based on a
cutoff equal to 2459 pg/mL, we divided
our cohort in 2 subsets (high and low
Ang2) composing 100 (31.6%) and 216
(68.4%) patients, respectively. High Ang2
was predictive of reduced TTFT (P < .001)
and overall survival (P  .002). Multivari-
ate analysis confirmed that high Ang2
was an independent prognosticator for
TTFT (hazard ratio  1.739; 95% confi-
dence interval, 1.059-2.857; P  .029).
Significant associations were found be-
tween high Ang2 and advanced Binet
stages (P < .001), high 2-microglobulin
(P < .001), unmutated variable region of
immunoglobulin heavy chain gene status
(P < .001), high CD38 and -chain-associ-
ated protein kinase 70 expression
(P < .001 and P  .003), and intermediate/
high cytogenetic risk (P  .005). More-
over, Ang2 added prognostic power to
other conventional prognosticators and
helped to refine prognosis among CLL
subsets with both high and low vascular
endothelial growth factor plasma levels.
Ang2 plasma level may be a useful inde-
pendent prognosticator for CLL. (Blood.
2010;116(4):584-592)
Introduction
The clinical course of patients with chronic lymphocytic leukemia
(CLL) is extremely heterogeneous, with survival ranging from less
than 1 to 2 years to more than 15 years. Some patients show
aggressive clinical course and die shortly after diagnosis resulting
from disease-related or treatment-related complications, whereas
others experience an indolent clinical course, never require therapy,
and eventually die of disease-unrelated causes. Because CLL
patients who will experience adverse clinical outcome may poten-
tially benefit from early therapy, it is crucial to assess accurately
patients’ prognosis at diagnosis.
Several prognostic factors are currently used for discriminating
patients with rapidly evolving disease from those with indolent
disease.1 A useful prognostic factor should be able to stratify
patients with different risk to progressive disease and shorter
survival. Its usefulness may be further increased if the prognostic
factor provides a potential therapeutic target because of its
involvement in disease pathobiology. Moreover, the technical
approach used to assess the prognostic factor should be easy,
reproducible, well standardized, and relatively inexpensive to be
included in routine clinical practice.
Angiopoietin-2 (Ang2) is a 75-kDa secreted glycoprotein able
to bind to the receptor tyrosine kinase Tie-2. Ang2 is a destabilizing
factor able to revert vessels to a more plastic state by blocking the
maturing function of Ang1. Ang2 works in concert with vascular
endothelial growth factor (VEGF) to determine angiogenic remod-
eling and sprouting. Ang2 activates endothelial cells and destabi-
lizes vessel structure; then VEGF promotes endothelial cell prolif-
eration and migration allowing the formation of new vessels.
Instead, in absence of VEGF, Ang2 promotes vessel regression.2,3
High levels of Ang2 were observed in highly vascularized tu-
mors.4,5 Moreover, preliminary studies in solid tumors showed that
disruption of Ang2 function can inhibit tumor vessel density and
growth, suggesting a role for Ang2 in tumor angiogenesis and
progression.6-8
In CLL, we have recently reported that: (1) Ang2 protein is
secreted by leukemic cells, (2) CLL cells induce increased angio-
genesis, and (3) angiogenesis in CLL is mediated by both
leukemia-derived VEGF and Ang2.9 These data suggest that Ang2
may be involved in CLL pathobiology. In addition, elevated levels
of Ang2 were reported to be associated with advanced-stage
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disease and shorter progression-free survival in a small number of
cases.10-12 These preliminary results prompted us to further investi-
gate the clinical significance of Ang2 plasmatic levels in a large
multicentric series of 316 CLL patients.
Methods
Patients
A total of 316 CLL patients diagnosed at the Divisions of Hematology of
Novara (n  115), Modena (n  58), Rome (n  56), Siena (n  52), and
Ferrara (n  35) during the years 1985 to 2008 were enrolled in this study.
Diagnosis was based on the National Cancer Institute-sponsored Working
Group guidelines on Chronic Lymphocytic Leukemia and reviewed accord-
ing to the new International Workshop on Chronic Lymphocytic Leukemia
criteria.13,14 Patients were selected according to the availability of plasma
samples collected in overt disease: 274 (86.7%) cases were untreated at
sample collection, whereas 42 (13.3%) patients had relapsed after previous
treatment and none had received chemotherapy within 3 months before
sample collection. During the course of the study, a further 53 (16.8%)
patients required therapy. The median follow-up was 48 months. At the time
of analysis, a total of 21 patients (6.6%) had died. All patients provided
informed consent in accordance with local institutional review board
requirements and the Declaration of Helsinki principles. The study was
approved by the ethical committee of the University of Modena and Reggio
Emilia. The clinical and biologic characteristics of our CLL cohort are
summarized in Table 1.
IGHV mutational analysis
To evaluate the mutational status of immunoglobulin heavy chain genes
(IGHVs) expressed by CLL clones, total RNA was extracted, reverse-
transcribed, and tumor variable region of IGHV DJ rearrangement was
amplified as previously described.15-17 Alternatively, IGHV DJ rearrange-
ments were amplified starting from genomic DNA as described elsewhere.18
The tumor-specific IGHV DJ sequence was aligned to ImMunoGeneTics
directories (http://imgt.cines.fr). IGHV gene sequences deviating more than
2% from the corresponding germline gene were defined as mutated.19
Immunophenotypic analyses of CD38, CD49d, and ZAP-70
All flow cytometric analyses reported in this study were performed on a
FACSCalibur flow cytometer (BD Biosciences). The expression of CD38
and CD49d was analyzed by 3-color immunofluorescence, as previously
described.20,21 Expression data were reported as percentage of CD5CD19
CLL cells displaying specific fluorescence intensity higher than the 98% to
99% of the same cell population stained with isotype- and fluorochrome-
matched control immunoglobulins. The detection of -chain-associated
protein kinase 70 (ZAP-70) was performed as previously reported.22
ZAP-70 intracellular expression was determined as percentage of CD19
CLL cells expressing the protein above the isotype control and/or above a
marker set to include as positive all autologous T cells. The cutoff of 30%
positive cells was chosen to discriminate CD38 from CD38 CLL or
CD49d from CD49d CLL.15,23,24 The cutoff of 20% was instead selected
to divide ZAP-70 from ZAP-70 CLL.25
Analysis of cytogenetic aberrations
Cytogenetic abnormalities on chromosomes 11, 12, 13, and 17 were
detected by interphase fluorescence in situ hybridization (FISH). The
3 locus specific probes LSI-ATM, LSI-D13S319, and LSI-p53, directly
labeled with SpectrumGreen (LSI-ATM) or SpectrumOrange (LSI-
D13S319 and LSI-p53), were used for chromosomes 11, 13, and
17, respectively (Vysis). An alpha satellite DNA probe CEP12, directly
labeled with SpectrumGreen, was used to identify aneuploidy of chromo-
some 12 (Vysis). The FISH procedures used for this study were previously
described.22,26
Quantification of Ang2 and VEGF plasma levels
Peripheral blood (PB) samples were collected from 316 CLL patients in the
presence of overt disease and anticoagulated in ethylenediaminetetraacetic
acid. To verify Ang2 level variations over time, a second blood sample was
collected from 35 cases in a subsequent time of the disease (29 of 35 before
treatment, 6 of 35 after treatment). Of note, all 6 previously treated patients
were relapsed at sample collection, and none had received chemotherapy
within 3 months before collection. Moreover, bone marrow (BM) and PB
blood samples collected at the same time were available for 14 patients.
Plasma samples were obtained by blood centrifugation at 1000g for
15 minutes and then stored at 20°C. Plasma samples were centralized to
the Division of Hematology of Modena for Ang2 and VEGF quantification.
Ang2 and VEGF plasma levels were quantified using Quantikine solid-
phase enzyme-linked immunosorbent Ang2 and VEGF assay (DANG20
and DVE00, ELISA; R&D Systems). The mean minimum detectable dose
was 8.3 pg/mL for Ang2 and less than 9.0 pg/mL for VEGF. Each plasma
sample was tested in duplicate, and concentrations were reported in
picograms per milliliter. The coefficient of variability intra-assay and
interassay was less than 5% and 10%, respectively, in all experiments.
Immunohistochemical staining for Ang2
Immunohistochemistry for Ang2 was performed on CLL-infiltrated BM
and lymph node (LN) biopsies collected at diagnosis from 8 patients.
Briefly, tissue sections were microwave treated 3 times in citrate buffer, pH
6 (Dako Denmark), for 5 minutes. After neutralization of the endogenous
peroxidase with H2O2 for 10 minutes, the slides were incubated with protein
block Novocastra (Leica Biosystems) for 10 minutes. Slides were then
incubated with the primary monoclonal antibody mouse anti–human Ang2
Table 1. Patient characteristics
Characteristic No. of patients (N  316) %
Median age, y 66 (33-90)
Median LDH, U/L (range; n  243) 338 (136-1432) —
Median 2-microglobulin, mg/L
(range; n  294) 2.2 (0.36-14.3) —
Sex
Male 177 56.0
Female 139 44.0
Binet stage (n  289)
A 242 83.7
B-C 47 16.3
BM pattern (n  149)
Not diffuse 125 83.9
Diffuse 24 16.1
IGHV mutational status (n  268)
Mutated ( 2%) 184 68.7
Unmutated ( 2%) 84 31.3
CD38 (n  308)
CD38 ( 30%) 233 75.6
CD38 ( 30%) 75 24.4
ZAP-70 (n  264)
ZAP-70 ( 20%) 160 60.6
ZAP-70 ( 20%) 104 39.4
CD49d (n  164)
CD49d ( 30%) 106 64.6
CD49d ( 30%) 58 35.4
FISH stratification (n  298)*
Low-risk 211 70.8
Intermediate/high-risk 87 29.2
Previous treatment
Yes 42 13.3
No 274 86.7
LDH indicates lactate dehydrogenase; and —, not applicable.
*Low-risk cytogenetic indicates no abnormalities or 13q; Intermediate/high-risk
cytogenetic, 11q, 17p, or trisomy 12.
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(MAB0983, R&D Systems, dilution 1:50). Normal mouse serum was used
instead of the primary antibody as negative control. Slides were subse-
quently incubated with biotinylated link antibody and peroxidase-labeled
streptavidin (Universal LSAB  System-HRP, Dako Denmark). The stain-
ing was revealed by incubation with 3-amino-9-ethylcarbazole substrate-
chromogen (Dako Denmark). After counterstaining with hematoxylin
(Dako Denmark), the slides were evaluated under a Leica DM3000 optical
microscope (Leica Microsystems) and images were collected using a Leica
DFC320 digital camera and Leica IM50 software (Leica Microsystems).
Statistical analyses
All data were analyzed using SPSS, Version 16.0 for Windows. The cutoff
point for Ang2 plasma levels was selected according to receiver operating
characteristic (ROC) analysis using treatment as state variable, and the
Youden index was calculated using the sensitivity and specificity derived
from ROC analysis. The Pearson 2 test was used to determine significant
differences in categorized variables. Furthermore, comparisons of distribu-
tions of continuous variables were performed with the Mann-Whitney test.
The Spearman test was used for estimating correlations between quantita-
tive parameters. The primary endpoints were time to first treatment (TTFT)
and overall survival (OS): TTFT was defined as time from diagnosis to first
treatment (event) or last follow-up, whereas OS was defined as time from
diagnosis to death (event) or last follow-up. For OS analyses, all events
were considered as CLL-related (ie, all deaths were considered as events
independently from the cause). TTFT and OS functions were estimated
using the product-limit (Kaplan-Meier) method, and the curves were
compared between groups using the log-rank test. Univariate and multivar-
iate analyses were performed using Cox models.27 Wilcoxon test and
concordance correlation coefficient were used to compare Ang2 levels
measured in plasma samples collected from the same patients in 2 different
times of the disease.28 All tests were 2-sided. An effect was considered
statistically significant at P less than or equal to .05.
Results
Ang2 plasma levels are an independent predictor of short TTFT
in CLL
We measured Ang2 level in PB plasma samples derived from
316 CLL patients using an enzyme-linked immunosorbent assay
(ELISA)-based method. Ang2 plasma levels ranged from 972 to
17 281 pg/mL with a median value of 2061 pg/mL (supplemental
Figure 1, available on the Blood Web site; see the Supplemental
Materials link at the top of the online article). The best cutoff point,
generated by ROC analysis and Youden index using treating as
state variable, was 2459 pg/mL. Based on the 2459 pg/mL cutoff,
the CLL cohort was divided into 2 groups (high Ang2 and low
Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respec-
tively. After a median observation from CLL diagnosis of
48 months, 95 of 316 patients have been treated, accounting for a
median TTFT of 40 months. Cox univariate analysis identified
Ang2 more than or equal to 2459 pg/mL as a predictor of reduced
TTFT (hazard ratio [HR]  2.437; 95% confidence interval [CI],
1.621-3.664, P  .001). Accordingly, patients with high Ang2 were
characterized by a significantly shorter TTFT (77.5 months)
compared with patients with low Ang2 (179.2 months; P  .001;
Figure 1A). Other variables associated with short TTFT were
advanced Binet stage, unmutated IGHV status, high CD38, ZAP-
70, and CD49d expression, intermediate/high cytogenetic risk,
high 2-microglobulin, and diffuse BM pattern (P  .001 in all
instances; Table 2). Multivariate analysis selected Ang2 more than
or equal to 2459 pg/mL as an independent predictor of TTFT
(HR  1.765; 95% CI, 1.052-2.960; P  .031) together with
advanced Binet stage (HR  5.917; 95% CI, 3.341-10.479;
P  .001), intermediate/high FISH risk (HR  3.116; 95% CI,
1.758-5.521; P  .001), and unmutated IGHV status (HR  2.269;
95% CI, 1.282-4.015; P  .005; supplemental Table 1). Because
advanced Binet stage at diagnosis may be per se an indication to
first-line treatment, the analysis was repeated after removing Binet
stage from the covariates. This model selected as predictors of
TTFT high Ang2 level (HR  1.739; 95% CI, 1.059-2.857;
P  .029) together with intermediate/high FISH risk (HR  3.272;
95% CI, 1.993-5.373; P  .001) and unmutated IGHV status
(HR  2.260; 95% CI, 1.340-3.812; P  .002). The same results
were obtained by limiting TTFT analysis only to the cohort of
274 CLL patients who did not receive treatment before this study
(supplemental Table 1).
At the time of the analysis, 21 of 316 CLL patients have died,
accounting for a median survival not reached and a 10-year
survival of 87.1%. Because the statistical power of survival
analysis was limited by the low number of deaths in this CLL
cohort, the impact of Ang2 levels on OS was only explored. Along
Figure 1. Kaplan-Meier curves for TTFT and OS in
316 CLLs. Patients are stratified in high and low Ang2
subsets based on Ang2 levels (cutoff, 2459 pg/mL). High
Ang2 CLLs display significantly shorter TTFT (A) and OS
(B) compared with low Ang2 CLLs (P  .001 and
P  .002, respectively; log-rank test).
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with TTFT, Ang2 more than or equal to 2459 pg/mL was also a
predictor of poor OS (HR 3.566; 95% CI, 1.496-8.499; P .004)
in CLL (Table 2). Accordingly, patients with high Ang2 were
characterized by a significantly shorter OS (10-year OS, 74%)
compared with patients with low Ang2 (10-year OS, 93%; P .002;
Figure 1B).
Ang2 plasma level refines prognosis among CLL subgroups
identified by conventional prognosticators
In our cohort of CLL patients, we found significant associations
between Ang2 plasma levels and other previously defined prognos-
ticators. Table 3 compares the distribution of CLL prognostic
factors between low Ang2 and high Ang2 CLL subgroups. High
Ang2 was associated with Binet stages B-C (P  .001), high
2-microglobulin (P  .001), unmutated IGHV status (P  .001),
high CD38 expression (P  .001), elevated ZAP-70 expression
(P  .003), and intermediate/high cytogenetic risk (P  .005). No
significant associations were found with the extent of infiltration
(P  .215) and BM pattern (P  .785).
However, a consistent percentage of patients showed high Ang2
levels in the presence of favorable prognosticators and vice versa:
these cases were defined as discordant and accounted for 80 of 289
(27.7%) patients for Binet stage, 83 of 268 (31.0%) for IGHV
mutational status, 97 of 308 (31.5%) for CD38 expression, 100 of
264 (37.9%) for ZAP-70 expression, 64 of 164 (39.0%) for CD49d
expression, 106 of 298 (35.6%) for FISH risk, and 111 of 294
(37.8%) for 2-microglobulin (Table 3). By analyzing these
discordances in greater depth, we found that high Ang2 level
identified a CLL subgroup displaying early need for treatment and
reduced survival despite being characterized at diagnosis by
favorable predictors, such as mutated IGHV status (P  .002 for
TTFT and P  .05 for OS, Figure 2A-B), low CD38 expression
(P  .001 for TTFT and P  .003 for OS), low ZAP-70 expression
(P  .039 for TTFT), low CD49d expression (P  .001 for TTFT),
low FISH risk (P  .001 for TTFT and P  .05 for OS, Figure
2C-D), and low 2-microglobulin (P  .013 for TTFT; supplemen-
tal Table 2). Moreover, low Ang2 levels identified a CLL subgroup
with longer TTFT and OS despite being characterized by advanced
Binet stage (P  .02 for TTFT and P  .032 for OS), high
expression of CD38 (P  .018 for TTFT), ZAP-70 (P  .005 for
TTFT and P  .05 for OS), and CD49d (P  .011 for OS), and
high 2-microglobulin (P  .019 for OS; supplemental Table 2).
Ang2 level retains the prognostic value for TTFT in CLL with
low and high VEGF
In physiologic and pathologic angiogenic processes, Ang2 is
functionally associated with VEGF. We evaluated the plasma levels
of VEGF protein in a subset of 160 CLL cases (supplemental Table
3). The subset of patients (cohort 2), investigated for both Ang2 and
VEGF, was defined by a random selection of 40 CLL cases from
each quartile of Ang2 distribution. In this way, the chosen CLL
subset was representative of the whole cohort: the patients’
characteristics were not statistically different, and the previously
reported analyses assessing Ang2 prognostic value were confirmed
in this 160 subset (data not shown). VEGF plasma levels ranged
from 0 to 614 pg/mL with a median value of 52 pg/mL. No
significant association was found between VEGF levels and all
conventional prognostic factors. Moreover, Ang2 and VEGF
plasma levels were not statistically correlated (r  0.22, P  .05).
Then, we evaluated the prognostic value of VEGF plasma levels for
TTFT. We first defined the median value as a cutoff to divide CLL
into high and low VEGF groups, obtaining no significant prognos-
tic value of VEGF for TTFT (median TTFT, 179 vs 104 months in
Table 2. Predictive risk of Ang2 plasma levels and main established CLL prognostic factors in relation to TTFT and overall survival
(univariate Cox models)
Factor
TTFT Overall survival
HR 95% CI P HR 95% CI P
Ang2 level  2459 pg/mL 2.437 1.621-3.664  .001 3.566 1.496-8.499 .004
Binet stages B-C 8.883 5.527-14.277  .001 6.860 2.743-17.155  .001
IGHV mutation  2% 4.342 2.792-6.754  .001 3.749 1.453-9.675 .006
CD38 expression  30% 2.647 1.738-4.029  .001 3.178 1.330-7.592 .009
ZAP-70 expression  20% 2.422 1.577-3.720  .001 2.666 0.950-7.486 .062
CD49d expression  30% 2.903 1.715-4.913  .001 7.019 2.179-22.607 .001
Intermediate/high FISH risk* 4.215 2.766-6.423  .001 2.531 0.995-6.435 .050
2-Microglobulin  2.2 mg/L 2.347 1.515-3.636  .001 17.727 2.369-132.633 .005
Diffuse BM pattern 3.750 2.017-6.972  .001 4.907 1.552-15.516 .007
*Intermediate/high-risk cytogenetic indicates 11q, 17p, or trisomy 12.
Table 3. Distribution of CLL prognostic factors according to Ang2
plasma levels
High Ang2 level, no. (%) P
Clinical stage  .001
Binet A 58/242 (24.0)
Binet B-C 25/47 (53.2)
IGHV mutational status  .001
Mutated 42/184 (22.8)
Unmutated 43/84 (51.2)
CD38  .001
CD38 ( 30%) 59/233 (25.3)
CD38 ( 30%) 37/75 (49.3)
ZAP-70 .003
ZAP-70 ( 20%) 40/160 (25.0)
ZAP-70 ( 20%) 44/104 (42.3)
CD49d .126
CD49d ( 30%) 28/106 (26.4)
CD49d ( 30%) 22/58 (37.9)
FISH stratification* .005
Low-risk 57/211 (27.0)
Intermediate/high-risk 38/87 (43.7)
2-Microglobulin  .001
Low ( 2.2 mg/L) 29/146 (19.9)
High ( 2.2 mg/L) 66/148 (44.6)
BM pattern .785
Diffuse 4/24 (2.7)
Not diffuse 27/125 (18.1)
*Low-risk cytogenetic indicates no abnormalities or 13q; Intermediate/high-risk
cytogenetic, 11q, 17p, or trisomy 12.
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low vs high VEGF group, P  .373). Then, we tested the 75th
percentile (148 pg/mL) as a cutoff, and we found that the subgroup
of CLL cases with very high VEGF ( 148 pg/mL) had signifi-
cantly shorter TTFT compared with low VEGF cases ( 148 pg/
mL; median TTFT, 176 vs 75 months in low vs high VEGF group,
P  .028; Figure 3A). Interestingly, Ang2 added prognostic power
to both high and low VEGF subsets. In particular, high Ang2
plasma level identified CLL with short TTFT among cases with low
VEGF (median TTFT, 179 vs 77 months in low vs high Ang2
group, P  .001; Figure 3B).
Ang2 is expressed by CLL cells in BM and LN compartments
We analyzed Ang2 expression by immunohistochemistry in CLL-
infiltrated BM and LN biopsies of 8 patients. In the BM compart-
ment, we found that Ang2 staining is mainly confined to marrow
infiltrating leukemic cells (Figure 4A-B). Notably, Ang2 expres-
sion was also observed in CLL cells with BM intravascular
distribution. In contrast, the other BM hematopoietic cells, as well
as stromal and endothelial cells, were mostly negative or slightly
reactive. Similarly to BM infiltrates, neoplastic cells diffusely
effacing LN architecture displayed a clear positivity to Ang2, and
such a reactivity did not involve endothelia (Figure 4C).
Furthermore, we measured Ang2 levels by ELISA in both PB
and BM plasma samples collected at the same time from 14 CLL
patients. A strong positive correlation was found between BM and
PB Ang2 levels (r  0.802; P  .001), although slightly lower
values were measured in the BM compartment compared with PB.
Moreover, no correlation was found between BM Ang2 plasma
levels and the degree of BM infiltration by CLL cells (r  0.140;
P  .632).
Ang2 level is not significantly modulated during disease
course
We performed comparison of Ang2 plasma levels between
2 sequential PB plasma samples collected from 35 CLL cases with
median interval of 19 months (range, 3-30 months). Six cases
received treatments between the 2 collections, and the second
plasma sample was obtained at relapse. No significant differences
(P  .376) in Ang2 levels over time in the same patient were
found. Of note, Ang2 plasma levels did not significantly change
among the sequential samples of both the 6 patients treated
between the 2 observations (P  .917) and the 29 cases not treated
between the 2 collections (P  .347; Figure 5). The overall
concordance correlation coefficient between sequential Ang2 plasma
levels was 0.757 (95% CI, 0.585-0.864), indicating a good stability
for Ang2. In particular, only 2 of 35 (6%) patients displayed
variations of Ang2 plasma levels between serial plasma samples
that implied a cutoff crossing (Figure 5).
Discussion
Previous evidence has shown that Ang2 might play a role in the
pathobiology and prognosis prediction of several solid tumors and
Figure 2. Prognostic relevance of Ang2 plasmatic
level in combination with other established prognos-
tic factors (IGHV and cytogenetic risk). Ang2 plasmatic
level in combination with IGHV mutational status (A-B)
and cytogenetic risk (C-D) carries a greater prognostic
power in defining TTFT and OS.
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hematologic malignancies.29-32 In particular, a strict association
between high Ang2 levels and more advanced disease, unfavorable
biologic prognostic parameters, and shorter progression-free sur-
vival was assessed in small series of CLL patients.10-12
On these premises, we reasoned that Ang2 would have a strong
rationale for being tested as an independent prognostic factor in
CLL. To test this hypothesis, we evaluated Ang2 plasma levels in a
large cohort of CLL cases using a rapid and easy commercial
ELISA kit. We measured variable amounts of Ang2 protein in
316 patients, and we identified Ang2 more than or equal to
2459 pg/mL as the best cutoff able to discriminate cases with
shorter TTFT and reduced OS. In particular, high Ang2 level is an
independent predictor of TTFT in multivariate analysis and is also a
negative prognosticator for OS because the difference in OS at
10 years from diagnosis between patients with low and high Ang2
level approximated 20%.
Given the increasing availability of biologic CLL prognostica-
tors, novel risk factors should provide information useful for
refining the prognosis of risk categories identified by already
existing markers. We therefore studied the association between
Ang2 dosage and main established CLL prognostic markers.
Patients with high Ang2 levels showed high prevalence of unfavor-
able prognostic parameters, but a relevant group of patients
harbored high Ang2 levels together with a favorable asset of
conventional markers or vice versa. In these discordant cases
(	 30% of patients), high Ang2 level refines prognosis by identify-
ing a subgroup of patients displaying short TTFT despite being
characterized by favorable predictors, including mutated IGHV,
low FISH risk, low CD38, ZAP-70, and CD49d expression, and
low 2-microglobulin. Conversely, low Ang2 levels soften the
unfavorable prognosis of patients with advanced Binet stage and
high CD38 and ZAP-70 expression.
In multiple myeloma, serum Ang2 levels showed a trend of
correlation with grade of BM involvement.33 In contrast, we found
Figure 4. Immunohistochemical staining for Ang2 protein in BM and LN
biopsies. In BM, Ang2 immunoreactivity is mainly confined to infiltrating CLL cells
(red), whereas other hematopoietic cells are mostly negative or slightly reactive (light
pink; A-B). Notably, Ang2 expression is detected also in CLL cells displaying an
intravascular distribution. No significant staining for Ang2 is observed on stromal and
endothelial cells (A-B insets). Neoplastic cells diffusely effacing LN architecture
display a clear positivity to Ang2, and such a reactivity does not involve endothelia
(C). Original magnification, 200
 for panels A and C, 400
 for panel B.
Figure 3. Prognostic value of Ang2 in combination with VEGF. (A) Patients are
stratified in high and low VEGF subsets based on VEGF plasma levels
(cutoff  148 pg/mL). High VEGF CLLs have significantly shorter TTFT compared
with low VEGF CLLs (P  .028, log-rank test). (B) Ang2 plasmatic level adds
prognostic power in defining TTFT inside CLL subsets with high and low VEGF
plasma level (P  .001). The cutoff level for Ang2 is 2459 pg/mL and for VEGF is the
75th percentile (148 pg/mL).
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absence of correlation between Ang2 and degree/pattern of marrow
infiltration in CLL, suggesting that increased Ang2 plasma levels
are the direct effect of abnormal production by CLL cells that had
experienced an “angiogenic switch,” not merely an index of extent
of CLL cells infiltrating BM. Moreover, the study of sequential
samples demonstrated that Ang2 levels are quite stable during the
disease course and that current treatments do not seem able to
interfere with Ang2 production by the CLL clone or do not select
for subclones with different angiogenic capacities. As a conse-
quence, higher Ang2 secretion seems to be a peculiar biologic
characteristic of more aggressive CLL, already present at the
beginning of the disease and maintained subsequently at relapse.
Our findings are subject to several limitations. First, the chosen
cutoff has to be confirmed in an independent cohort of patients.
Second, it would be important to study extensively Ang2 dosage
trends in particular subsets of patients, such as those with renal
impairment,34 cardiovascular disease, or essential hypertension,35
because these comorbidities may per se affect, at least in part, Ang2
levels. Finally, given the long natural history of CLL, also the
observation of the stability of Ang2 levels during the disease course
needs to be confirmed in a larger series with a longer follow-up.
Angiogenesis is a multistep process tightly regulated by several
proangiogenic and antiangiogenic factors. Ang2 blocks the stabiliz-
ing action of the Tie-2 receptor, thus making vessels either more
susceptible to the angiogenic effect of agents such as VEGF or
more vulnerable to regression in absence of other angiogenic
support.36 As a consequence, Ang2 works under the influence of
VEGF. VEGF (both isoforms VEGF121 and VEGF165) is secreted
by CLL cells and induces functional angiogenesis.37 Moreover,
mean serum VEGF levels were higher in CLL compared with
normal controls, even if aberrant VEGF increase was found only in
a portion (	 18%) of patients.38,39 Importantly, CD38 CLL cells
overexpressed VEGF and appeared to preferentially use an internal
autocrine VEGF survival loop.40 Conflicting results were reported
about the prognostic role of plasma/serum VEGF levels.39,41-44 We
evaluated plasma VEGF levels in 160 CLLs, finding that cases with
very high VEGF ( 148 pg/mL, 75th percentile) had significant
shorter TTFT compared with low VEGF cases. Interestingly, poor
prognosis in patients with high Ang2 plasma levels was evident in
both high and low VEGF subsets, implying that abundant Ang2
production manifests its adverse effect independently from the
extent of VEGF secreted by CLL.
Ang2 seems to be an interesting molecule among other angio-
genesis-related factors. The immunohistochemical study of Ang2
expression in BM and LN compartments infiltrated by CLL cells
revealed that Ang2 preferentially originates from leukemic cells
and not from activated endothelial or other surrounding cells.
Moreover, abnormal Ang2 production seems to be a feature
acquired precociously by CLL and maintained during the disease
course. A genome-wide array-based methylation analysis recently
found that ANG2 gene was methylated in mutated CLL while being
unmethylated in unmutated CLL, underlining a role of epigenetic
changes in the increased Ang2 expression by the CLL subset with
poor prognosis.45 Finally, high Ang2 shows strong and independent
prognostic power.
Elucidation of the underlying reasons for poor outcome of CLL
patients showing high levels of Ang2 prompts further studies. The
imbalance toward proangiogenic cytokine production (angiogenic
switch) and, as consequence, sprouting of new blood vessels in BM
and LNs may provide oxygen and metabolite supply, increase cell
mobility, and enhance survival circuits, thus facilitating disease
progression. Of interest, in vitro interaction between CLL cells and
endothelial cells was showed to promote CLL survival.46-48 The
association between Ang2 and other poor prognostic parameters
(unmutated IGHV, CD38, ZAP-70, and CD49d) in our study
implies that the leukemic clone with these molecular properties
may be characterized by favorable angiogenic milieu and increased
stromal nurturing.48,49
The pathways activated by Ang2 in CLL microenvironment
deserve particular attention to identify new possible pathogenetic
mechanisms and related therapeutic targets. Because several mol-
ecules targeting microenvironment and angiogenesis are being
developed in clinical trials for CLL, it could be also intriguing to
evaluate if such drugs may modulate Ang2 secretion. Blockade of
Ang2 using inhibitors of nox enzymes or using selective antibodies
and peptide-Fc fusion proteins was shown to reduce vasculariza-
tion and growth in mouse models of several solid tumors.6-8
Moreover, AMG 386, a selective angiopoietin inhibitor has re-
cently been tested in patients with advanced solid tumors, and it
would be interesting to know its role in CLL.50
In conclusion, we first demonstrate the prognostic role of Ang2
plasma levels in CLL, in relation to TTFT and OS. Moreover, we
show that Ang2 contributes to refine the prognostic assessment of
CLL when used in combination with the other prognostic markers.
Figure 5. Stability of Ang2 plasma
level during the course of CLL. The
comparison between 2 sequential
plasma samples derived from 35 CLL
patients shows no statistical differ-
ence in Ang2 level both for the
6 treated cases (left) and for the
29 untreated patients (right; P  .917
and P  .347, respectively, Wilcoxon
test).
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Our observations are supported by the finding of the stability of
Ang2 dosage during the disease course and suggest an important
role of this molecule inside CLL pathogenesis. This study implies a
simple and reproducible ELISA method that could be therefore
easily used both in clinical practice and in further studies, helping
to better refine prognosis, understand CLL pathogenesis, and
identify target therapies.
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